Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Bidirectional Cross-talk Between Estrogen Receptor and Growth Factor Receptors in Breast Cancer Cell

유방암세포에서 에스트로겐 수용체와 성장인자 수용체 사이의 양방향 상호작용

  • Min, Gyesik (Department of Nursing, College of Life Science, Gyeongnam National University of Science & Technology)
  • 민계식 (경남과학기술대학교 생명과학대학 간호학과)
  • Received : 2018.02.14
  • Accepted : 2018.02.21
  • Published : 2018.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Estrogen (E2) is involved in the development and progression of breast cancer and is mediated by estrogen receptor (ER). ER plays important roles in cellular proliferation, migration, invasion and causing drug resistance through diverse cross-talks with epidermal growth factor receptor (EGFR) and insulin-like growth factor-1 receptor (IGF-1R) signaling pathways in breast cancer cells. Breast cancer is caused mainly by break-down of homeostasis of endocrine signaling pathways especially by the uncontrolled expression and increased activities of E2/IGF-1/EGF, ER/G-protein estrogen receptor (GPER)/IGF-1R/EGFR and their intracellular signaling mediators. These changes influence the complex cross-talk between E2 and growth factors' signaling, eventually resulting in the progression of cancer and resistance against endocrine regulators. Thus, elucidation of the molecular mechanisms in stepwise of the cross-talk between E2 and growth factors will contribute to the customized treatment according to the diverse types of breast cancer. In particular, as strategies for the treatment of breast cancer with diverse genotypes and phenotypes, there can be use of aromatase inhibitors and blockers of E2 action for the ER+ hormone-dependent breast cancer cells and use of IGF-1R/EGFR activity blockers for suppression of cancer cell proliferation from the cross-talk between E2 and growth factors. Furthermore, changes in the expression of the ECM molecules regulated by the cross-talk between ER and EGFR/IGF-1R can be used for the targeted therapeutics against the migration of breast cancer cells. Therefore, it is required for the cross-talk among the signaling pathways of ER, GPER, IGF-1R and EGFR concerning cancer progression to be elucidated in more detail at the molecular level.

에스트로겐(E2)은 유방암의 발달과 진행에 관여하며, 에스트로겐 수용체(ER)에 의해 매개된다. ER은 유방암세포에서 epidermal growth factor receptor와 insulin-like growth factor-1 receptor의 신호전달경로들 사이에서 다양한 cross-talk을 통하여 세포의 증식, 이주, 침습 및 약물에 대한 저항성을 일으키는데 중요한 역할을 수행한다. 유방암은 내분비신호전달의 항상성 붕괴에 의해 주로 발생되며, 특히 E2/IGF-1/EGF와 ER/G-protein estrogen receptor (GPER)/IGF-1R/EGFR, 그리고 이들의 세포내 신호전달 매개인자들의 통제되지 않는 발현과 활성증가에 의해 유발된다. 이러한 변화는 E2와 성장인자 신호전달 사이의 복잡한 cross-talk에 영향을 주어 결국 암의 진행과 내분비조절인자들에 대한 저항성을 갖게 된다. 따라서, E2와 성장인자들 사이의 cross-talk에 관한 분자적 기전을 단계별로 규명하는 것은 유방암의 다양한 유형에 따른 맞춤형 치료에 기여할 것으로 사료된다. 특히, 다양한 유전형 및 표현형을 가진 유방암의 치료를 위한 전략으로서, ER+ 호르몬의존성 유방암세포에 대한 aromatase 억제제 및 E2작용 차단제의 사용과 E2와 성장인자들 사이의 cross-talk에 의한 암세포의 증식억제를 위한 IGF-1R/EGFR 활성차단제의 사용 등을 들 수 있다. 뿐만 아니라, ER과 EGFR/IGF-1R 사이의 cross-talk에 의해 조절되는 ECM 분자들의 발현변화는 유방암세포의 전이에 대한 표적치료제를 위해 활용될 수 있다. 따라서, 암의 진행과 관련된 ER, GPER, IGF-1R 및 EGFR 매개에 의한 신호전달경로들 사이의 cross-talk에 관한 보다 더 자세한 분자적 수준의 규명이 필요할 것으로 사료된다.

Keywords

References

  1. Ahmad, T., Farnie, G., Bundred, N. J. and Anderson, N. G. 2004. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J. Biol. Chem. 279, 1713-1719. https://doi.org/10.1074/jbc.M306156200
  2. Alexaki, V. I., Charalampopoulos, I., Kampa, M., Vassalou, H., Theodoropoulos, P., Stathopoulos, E. N., Hatzoglou, A., Gravanis, A. and Castanas, E. 2004. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J. 18, 1594-1596. https://doi.org/10.1096/fj.04-1495fje
  3. Ali, S. and Coombes, R. C. 2002. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2, 101-112. https://doi.org/10.1038/nrc721
  4. Allred, D. C. and Mohsin, S. K. 2000. Biological features of premalignant disease in the human breast. J. Mammary Gland Biol. Neoplasia 5, 351-364. https://doi.org/10.1023/A:1009573710675
  5. Allred, D. C. 2010. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod. Pathol. 23, S52-S59. https://doi.org/10.1038/modpathol.2010.55
  6. Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., Wilkinson, R., Qizilbash, A., Ambus, U., Lipa, M., Weizel, H., Katz, A., Baida, M., Mariz, S., Stoik, G., Dacamara, P., Strongitharm, D., Geddie, W. and Mc-Cready, D. 1998. neu/erbB-2 amplification identifies a poorprognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J. Clin. Oncol. 16, 1340-1349. https://doi.org/10.1200/JCO.1998.16.4.1340
  7. Arias-Pulido, H., Royce, M., Gong, Y., Joste, N., Lomo, L., Lee, S. J., Chaher, N., Verschraegen, C., Lara, J., Prossnitz, E. R. and Cristofanilli, M. 2010. GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast Cancer Res. Treat. 123, 51-58. https://doi.org/10.1007/s10549-009-0631-7
  8. Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., De Placido, S., Osborne, C. K. and Schiff, R. 2007. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER targeted therapy. J. Natl. Cancer Inst. 99, 694-705. https://doi.org/10.1093/jnci/djk151
  9. Ascenzi, P., Bocedi, A. and Marino, M. 2006. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 27, 299-402. https://doi.org/10.1016/j.mam.2006.07.001
  10. Azios, N. G. and Dharmawardhane, S. F. 2005. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDAMB-231 human breast cancer cells. Neoplasia 7, 128-140. https://doi.org/10.1593/neo.04346
  11. Baserga, R., Peruzzi, F. and Reiss, K. 2003. The IGF-1 receptor in cancer biology. Int. J. Cancer 107, 873-877. https://doi.org/10.1002/ijc.11487
  12. Becker, M. A., Ibrahim, Y. H., Cui, X., Lee, A. V. and Yee, D. 2011. The IGF pathway regulates $ER{\alpha}$ through a S6K1-dependent mechanism in breast cancer cells. Mol. Endocrinol. 25, 516-528. https://doi.org/10.1210/me.2010-0373
  13. Belfiore, A. 2007. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr. Pharm. Des. 13, 671-686. https://doi.org/10.2174/138161207780249173
  14. Belfiore, A., Frasca, F., Pandini, G., Sciacca, L. and Vigneri, R. 2009. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr. Rev. 30, 586-623. https://doi.org/10.1210/er.2008-0047
  15. Brufsky, A. M. and Dickler, M. N. 2018. Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance. Oncologist doi: 10.1634/theoncologist.2017-0423.
  16. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S. and Nakshatri, H. 2001. Endocrine-responsive breast cancer and strategies for combating phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276, 9817-9824. https://doi.org/10.1074/jbc.M010840200
  17. Catalano, S., Giordano, C., Panza, S., Chemi, F., Bonofiglio, D., Lanzino, M., Rizza, P., Romeo, F., Fuqua, S. A., Maggiolini, M., Ando, S. and Barone, I. 2014. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res. Treat. 146, 273-285. https://doi.org/10.1007/s10549-014-3017-4
  18. De Marco, P., Cirillo, F., Vivacqua, A., Malaguarnera, R., Belfiore, A. and Maggiolini, M. 2015. Novel aspects concerning the functional cross-talk between the insulin/IGF-I system and estrogen signaling in cancer cells. Front. Endocrinol. (Lausanne) 6, PMCID: PMC4351617.
  19. Fox, E. M., Andrade, J. and Shupnik, M. A. 2009. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 74, 622-627. https://doi.org/10.1016/j.steroids.2008.10.014
  20. Gaben, A. M., Sabbah, M., Redeuilh, G., Bedin, M. and Mester, J. 2012. Ligand-free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer 12, doi: 10.1186/1471-2407-12-291.
  21. Giovannucci, E., Pollak, M., Liu, Y., Platz, E. A., Majeed, N., Rimm, E. B. and Willett, W. C. 2003. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol. Biomarkers Prev. 12, 84-89.
  22. Bado, I, Gugala, Z., Fuqua, S. A.W. and Zhang, X. H. 2017. Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene 36, 4527-4537. https://doi.org/10.1038/onc.2017.94
  23. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E. and Pollak, M. 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 359, 1393-1396.
  24. Hart, S., Fischer, O. M., Prenzel, N., Zwick-Wallasch, E., Schneider, M., Hennighausen, L. and Ullrich, A. 2005. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 386, 845-855.
  25. Hay, N. and Sonenberg, N. 2004. Upstream and downstream of mTOR. Genes Dev. 18, 1926-1945. https://doi.org/10.1101/gad.1212704
  26. Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Strom, A., Treuter, E., Warner, M. and Gustafsson, J. A. 2007. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 87, 905-931. https://doi.org/10.1152/physrev.00026.2006
  27. Hers, I., Vincent, E. E. and Tavare, J. M. 2011. Akt signalling in health and disease. Cell. Signal. 23, 1515-1527. https://doi.org/10.1016/j.cellsig.2011.05.004
  28. Hurtado, A., Holmes, K. A., Geistlinger, T. R., Hutcheson, I. R., Nicholson, R. I., Brown, M., Jiang, J., Howat, W. J., Ali, S. and Carroll, J. S. 2008. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456, 663-666. https://doi.org/10.1038/nature07483
  29. Jin, K., Park, S., Teo, W. W., Korangath, P., Cho, S. S., Yoshida, T., Gyorffy, B., Goswami, C. P., Nakshatri, H., Cruz, L. A., Zhou, W., Ji, H., Su, Y., Ekram, M., Wu, Z., Zhu, T., Polyak, K. and Sukumar, S. 2015. HOXB7 is an $ER{\alpha}$ cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov. 5, 944-959. https://doi.org/10.1158/2159-8290.CD-15-0090
  30. Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R. and Grohe, C. 2000. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 275, 19447-18453. https://doi.org/10.1074/jbc.M910345199
  31. Kato, S., Masuhiro, Y., Watanabe, M., Kobayashi, Y., Takeyama, K. I., Endoh, H. and Yanagisawa, J. 2000. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5, 593-601. https://doi.org/10.1046/j.1365-2443.2000.00354.x
  32. Kousidou, O., Berdiaki, A., Kletsas, D., Zafiropoulos, A., Theocharis, A. D., Tzanakakis, G. N. and Karamanos, N. K. 2008. Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol. Oncol. 2, 223-232. https://doi.org/10.1016/j.molonc.2008.06.002
  33. Lanzino, M., Morelli, C., Garofalo, C., Panno, M. L., Mauro, L., Ando, S. and Sisci, D. 2008. Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer. Curr. Cancer Drug Targets 8, 597-610. https://doi.org/10.2174/156800908786241104
  34. Lau, K. M., LaSpina, M., Long, J. and Ho, S. M. 2000. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 60, 3175-3182.
  35. Lee, A. V., Weng, C. N., Jackson, J. G. and Yee, D. 1997. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J. Endocrinol. 152, 39-47. https://doi.org/10.1677/joe.0.1520039
  36. Luo, H., Yang, G., Yu, T., Luo, S., Wu, C., Sun, Y., Liu, M. and Tu, G. 2014. GPER-mediated proliferation and estradiol production in breast cancer-associated fibroblasts. Endocr. Relat. Cancer 21, 355-369. https://doi.org/10.1530/ERC-13-0237
  37. Maor, S., Mayer, D., Yarden, R. I., Lee, A. V., Sarfstein, R., Werner, H. and Papa, M. Z. 2006. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. J. Endocrinol. 191, 605-612. https://doi.org/10.1677/joe.1.07016
  38. Marotti, J. D., Collins, L. C., Hu, R. and Tamimi, R. M. 2010. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod. Pathol. 23, 197-204. https://doi.org/10.1038/modpathol.2009.158
  39. Martin, M. B., Franke, T. F., Stoica, G. E., Chambon, P., Katzenellenbogen, B. S., Stoica, B. A., McLemore, M. S., Olivo, S. E. and Stoica, A. 2000. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 141, 4503-4511. https://doi.org/10.1210/endo.141.12.7836
  40. Mauro, L., Salerno, M., Panno, M. L., Bellizzi, D., Sisci, D., Miglietta, A., Surmacz, E. and Ando, S. 2001. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem. Biophys. Res. Commun. 288, 685-689. https://doi.org/10.1006/bbrc.2001.5815
  41. Mitropoulou, T. N., Tzanakakis, G. N., Kletsas, D., Kalofonos, H. P. and Karamanos, N. K. 2003. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int. J. Cancer 104, 155-160. https://doi.org/10.1002/ijc.10941
  42. Mook, S., Van 't Veer, L. J., Rutgers, E. J., Ravdin, P. M., van de Velde, A. O., van Leeuwen, F. E., Visser, O. and Schmidt, M. K. 2011. Independent prognostic value of screen detection in invasive breast cancer. J. Natl. Cancer Inst. 103, 585-597. https://doi.org/10.1093/jnci/djr043
  43. Nahta, R. 2012. Pharmacological strategies to overcome HER2 cross-talk and trastuzumab resistance. Curr. Med. Chem. 19, 1065-1075. https://doi.org/10.2174/092986712799320691
  44. Nardone, A., De Angelis, C., Trivedi, M. V., Osborne, C. K. and Schiff, R. 2015. The changing role of ER in endocrine resistance. Breast S2, S60-S66.
  45. Nicholson, R. I. and Johnston, S. R. 2005. Endocrine therapy--current benefits and limitations. Breast Cancer Res. Treat. 93, S3-S10.
  46. Osborne, C. K. and Schiff, R. 2011. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247. https://doi.org/10.1146/annurev-med-070909-182917
  47. Paruthiyil, S., Parmar, H., Kerekatte, V., Cunha, G. R., Firestone, G. L. and Leitman, D. C. 2004. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64, 423-428. https://doi.org/10.1158/0008-5472.CAN-03-2446
  48. Prossnitz, E. R. and Barton, M. 2014. Estrogen biology: new insights into GPER function and clinical opportunities. Mol. Cell. Endocrinol. 389, 71-83. https://doi.org/10.1016/j.mce.2014.02.002
  49. Rettberg, J. R., Yao, J. and Brinton, R. D. 2014. Estrogen: a master regulator of bioenergetic systems in the brain and body. Front. Neuroendocrinol. 35, 8-30. https://doi.org/10.1016/j.yfrne.2013.08.001
  50. Rozengurt, E. 2007. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell. Physiol. 213, 589-602. https://doi.org/10.1002/jcp.21246
  51. Rozengurt, E., Sinnett-Smith, J. and Kisfalvi, K. 2010. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16, 2505-2511. https://doi.org/10.1158/1078-0432.CCR-09-2229
  52. Saha, Roy. S. and Vadlamudi, R. K. 2012. Role of estrogen receptor signaling in breast cancer metastasis. Int. J. Breast Cancer doi: 10.1155/2012/654698.
  53. Samani, A. A., Yakar, S., LeRoith, D. and Brodt, P. 2006. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47.
  54. Sisci, D., Morelli, C., Cascio, S., Lanzino, M., Garofalo, C., Reiss, K., Garcia, M., Russo, A., Ando, S. and Surmacz, E. 2007. The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann. Oncol. S6, 81-85.
  55. Sjostrom, M., Hartman, L., Grabau, D., Fornander, T., Malmstrom, P., Nordenskjold, B., Sgroi, D. C., Skoog, L., Stal, O., Leeb-Lundberg, L. M., Ferno, M. 2014. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. Breast Cancer Res. Treat. 145, 61-71. https://doi.org/10.1007/s10549-014-2936-4
  56. Skandalis, S. S., Afratis, N., Smirlaki, G., Nikitovic, D., Theocharis, A. D., Tzanakakis, G. N. and Karamanos, N. K. 2014. Cross-talk between estradiol receptor and EGFR/I GF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans. Matrix Biol. 35, 182-193. https://doi.org/10.1016/j.matbio.2013.09.002
  57. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire, W. L. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 235, 177-182. https://doi.org/10.1126/science.3798106
  58. Song, R. X., Barnes, C. J., Zhang, Z., Bao, Y., Kumar, R. and Santen, R.J. 2004. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. PNAS 101, 2076-2081. https://doi.org/10.1073/pnas.0308334100
  59. Stattin, P., Rinaldi, S., Biessy, C., Stenman, U. H., Hallmans, G. and Kaaks, R. 2004. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J. Clin. Oncol. 22, 3104-3112. https://doi.org/10.1200/jco.2004.22.14_suppl.3104
  60. Thaler, S., Schmidt, M., RoBwag, S., Thiede, G., Schad, A. and Sleeman, J. P. 2017. Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Oncotarget 8, 72281-72301.
  61. Tisman, G. 2009. Inhibition of HER2/estrogen receptor cross-talk, probable relation to prolonged remission of stage IV breast cancer: a case report. Tumori 95, 804-807. https://doi.org/10.1177/030089160909500625
  62. Tsonis, A. I., Afratis, N., Gialeli, C., Ellina, M. I., Piperigkou, Z., Skandalis, S. S., Theocharis, A. D., Tzanakakis, G. N. and Karamanos, N. K. 2013. Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin-like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS J. 280, 2248-2259. https://doi.org/10.1111/febs.12162
  63. Vivacqua, A., Lappano, R., De Marco, P., Sisci, D., Aquila, S., De Amicis, F., Fuqua, S. A., Ando, S. and Maggiolini, M. 2009. G protein-coupled receptor 30 expression is upregulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol. Endocrinol. 23, 1815-1826. https://doi.org/10.1210/me.2009-0120
  64. Weigel, N. L. and Zhang, Y. 1998. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76, 469-479. https://doi.org/10.1007/s001090050241
  65. Woodward, T. L., Xie, J., Fendrick, J. L. and Haslam, S. Z. 2000. Proliferation of mouse mammary epithelial cells in vitro: interactions among epidermal growth factor, insulinlike growth factor I, ovarian hormones, and extracellular matrix proteins. Endocrinology 141, 3578-3586. https://doi.org/10.1210/endo.141.10.7701